Immutep Limited Announces Milestone Payment From Chinese Partner EOC Pharma
January 31, 2018 22:01 ET
|
Immutep Limited
SYDNEY, Australia, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) announced today that it has received a milestone payment from the Company’s Chinese partner for...
Operational Update
December 12, 2017 01:55 ET
|
Immutep Limited
SYDNEY, Australia, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (Immutep or the Company), has provided an update on the Company’s two ongoing clinical trials with...
Prima BioMed Becomes Immutep
November 27, 2017 19:12 ET
|
Prima BioMed Ltd
SYDNEY, Australia, Nov. 28, 2017 (GLOBE NEWSWIRE) -- We refer to shareholder approval granted at the Company’s Annual General Meeting held on 17 November 2017 to change the name of the Company from...
Prima Secures European Patent Grant for Lead Product IMP321 in Cancer
November 21, 2017 18:07 ET
|
Prima BioMed Ltd
SYDNEY, Australia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”, the “Company”) announces the grant of patent number 2604275 entitled “Use of Recombinant LAG-3...
Prima BioMed Changes Its Name to Immutep Ltd
November 20, 2017 01:59 ET
|
Prima BioMed Ltd
SYDNEY, Australia, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) has announced a rebranding of the Company from Prima BioMed Ltd to Immutep...
Eftilagimod Alpha (LAG-3Ig Or IMP321) Pre-IND Meeting With the FDA
November 15, 2017 03:11 ET
|
Prima BioMed Ltd
SYDNEY, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) is pleased to announce that it held a Pre-Investigational New Drug Application (pre-IND)...
New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
November 08, 2017 17:45 ET
|
Prima BioMed Ltd
SYDNEY, Australia, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) is pleased to announce the presentation of new data from its TACTI-mel Phase I clinical trial...
Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017
October 31, 2017 19:15 ET
|
Prima BioMed Ltd
SYDNEY, Australia, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer and Medical Officer,...
Dr. Frédéric Triebel Presenting at the World Immunotherapy Congress 2017
October 19, 2017 23:22 ET
|
Prima BioMed Ltd
SYDNEY, Australia, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ: PBMD) (“Prima”) announces that Dr. Frédéric Triebel, Prima’s Chief Scientific Officer & Medical Officer,...
IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
October 17, 2017 00:36 ET
|
Prima BioMed Ltd
SYDNEY, Australia, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”) announces that new data investigating the use of eftilagimod alpha (IMP321), the Company’s...